TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of acute ischemic stroke with onset within 5 hours and 30 minutes before randomization and planned treatment initiation within 6 hours of onset~* After 600 patients are enrolled in previous criteria, the new criteria for enrollment will be, patients with diagnosis of acute ischemic stroke with onset within 4 hours and 30 minutes before randomization and planned treatment initiation within 5 hours of onset~Exclusion Criteria:~* Patients who had participation in another study with an investigational drug or device within the last 30 days, prior participation in the present study, or planned participation in another trial~* Patients with symptoms suggestive of subarachnoid hemorrhage~* Female patients known to be pregnant, lactating, or having a positive or indeterminate pregnancy test~* Patients with neurological deficit that has led to stupor or coma~* Patients with minor stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Periodontal Infection and Prematurity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age between 6 and 20 completed weeks~Exclusion Criteria:~* Periodontal treatment during the pregnancy~* Antibiotic use within 2 weeks of enrollment~* Use of antimicrobial mouthwash within 2 weeks~* Multiple gestation~* Known mitral valve prolapse

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years and ≤75 years in age~* Patients with relapsed or refractory AML~* No more than one prior stem cell transplant~* Has not received the chemotherapy regimen to be used for induction on this trial~* Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial~Exclusion Criteria:~* Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.~* Active signs or symptoms of CNS involvement by malignancy.~* Stem cell transplantation ≤4 months prior to dosing.~* Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.~* Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.~* Inadequate organ function.~* Abnormal liver function.~* Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.~* Moderate kidney dysfunction (glomerular filtration rate \<45 mL/min).~* Uncontrolled acute life-threatening bacterial, viral, or fungal infection.~* Clinically significant cardiovascular disease.~* Major surgery within 4 weeks of dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Uproleselan (GMI-1271) (Type: EXPERIMENTAL): Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)
- Placebo (Saline, 0.9% Sodium Chloride) (Type: PLACEBO_COMPARATOR): Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) or fludarabine, cytarabine and idarubicin (FAI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer meeting 1 of the following stage criteria:~  * Stage IIIB~    * Pleural fluid and/or supraclavicular nodes allowed provided patient is not eligible for consolidation radiotherapy~ * Stage IV disease~* No disease progression after 2-6 courses of prior platinum-containing first-line palliative induction chemotherapy~* Brain metastases allowed provided patients are asymptomatic after cranial irradiation completed at least 4 weeks ago~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Pulmonary~* No history, signs, or symptoms of clinically active interstitial lung disease~  * Patients with chronic, stable, asymptomatic radiographic changes are eligible~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up~* No other malignant disease within the past 5 years except basal cell skin cancer or adequately treated superficial carcinoma of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunotherapy~Chemotherapy~* See Disease Characteristics~* Recovered from prior chemotherapy (alopecia allowed)~* No concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~Surgery~* Not specified~Other~* No prior epidermal growth factor receptor inhibitors~* No concurrent administration of any of the following drugs:~  * Phenytoin~ * Carbamazepine~ * Rifampin~ * Phenobarbital~ * Hypericum perforatum (St. John's wort)~* No other concurrent anticancer therapy~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Omega 3 FA Supplements as Augmentation in the Treatment of Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosed with depression and have cardiovascular disease, diabetes or cancer.~* Able to provide written informed consent prior to initiation of any study-related procedures.~* Able to understand and comply with the requirements of the study.~Exclusion Criteria:~* Hospitalized patients or psychotherapy for depression begun within 4 weeks.~* Patients with medically reversible causes of depression (e.g. hypothyroidism).~* Patients with significant comorbid symptoms (e.g. pain, insomnia) that have a direct causal relation to depressive and anxiety symptoms with these comorbid symptoms dominating the clinical scenario. Patients will be enrolled in the study if these comorbid symptoms merely coexist with depressive and anxiety symptoms and are not dominating the clinical scenario as judged by the study investigator~* Patients with an identifiable diagnosis of substance abuse or dependence within 6 months prior to evaluation (except those in full remission, or those with caffeine or nicotine dependence) as defined by DSM-IV criteria.~* Patients with any clinically significant unstable or inadequately treated co-morbid medical condition which, in the opinion of the investigator, would make the patient unsuited for the study~* Patients with currently active or with significant history of other clinically significant psychiatric disorders such as bipolar disorder, schizophrenia etc.~* Pregnant patients, breastfeeding or those planning to become pregnant during the study.~* Any other condition, which, in the opinion of the investigator, would make the patient, unsuited for enrollment in the study, including known or suspect history of allergy to fish oil, fish or desvenlafaxine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine + Omega 3 FA supplement (Type: EXPERIMENTAL): Desvenlafaxine 50mg/day \& Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period
- Desvenlafaxine + Placebo (for Omega 3 FA supplement) (Type: ACTIVE_COMPARATOR): Desvenlafaxine 50mg/day \& Placebo (for Omega 3 FA supplement) over a 12 week period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Application of S26E for Diabetic Foot Ulcer Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or type 2 Diabetes Mellitus~* Body Mass Index \<40 kg/m2~* Glycated Hemoglobin (HbA1c) \<10%~* Presence of a diabetic foot ulcer with the following features i) Owing to chronic peripheral sensorimotor diabetic neuropathy, with or without peripheral arterial disease (critical ischemia excluded as indexed by an Ankle-Brachial index \<0.4 ) ii) Persistence for \>12 weeks iii) Already following an adequate off-loading method~Exclusion Criteria:~* Presence of clinical signs of infection~* Inability or refusal to follow off-loading methods~* Ulcer surface area decline by \>15% during the run-in period~* Malignant disease (non-melanoma skin malignancy and healed thyroid malignancies excluded)~* Acute Charcot arthropathy~* Serious chronic Hepatic (Child-Pugh B or C), Renal (stage 4-5 CKD) or Heart (NYHA 3-4) disease~* Known hypersensitivity to the product or its contents~* Any random glucose measurement \>350 mg/dl during the run-in period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard-of-care managed group (Type: ACTIVE_COMPARATOR): This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers
- S26E (Type: EXPERIMENTAL): This group will receive the optimal standard-of-care for neuropathic/neuroischemic diabetic foot ulcers plus daily S26E application

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Are a healthy adult subject aged 18 years or older with no known significant health problems~* Are willing to refrain from wearing contact lens for the duration of the study~* Are willing and able to comply with clinic visits and study related procedures~* Are willing and able to sign the informed consent form~Exclusion Criteria:~* Have known significant health problems~* Are women of reproductive potential~* Are breastfeeding~* Are a known steroid responder~* Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye~* Have a history of complete punctal occlusion in one or both punctum~* Currently use topical ophthalmic steroid medications~* Are unwilling or unable to comply with the study protocol~* Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Novel Intracanalicular Insertion Device (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Implant Supported Oral Appliance Treatment of OSA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~This trial will recruit 10 patients with an objective diagnosis of obstructive sleep apnea who are not naïve to treatment. The inclusion criteria are:~* Currently receive or have previously received successful OSA treatment with an OAm;~* Age 25 - 65 years old, who are able to freely provide informed consent;~* Body Mass Index (BMI) ≤ 35;~* Apnea-Hypopnea Index (AHI) within the range 5≤AHI≤50 documented with polysomnography in the last 2 years \*\*\*OR\*\*\*~* Respiratory Disturbance Index (RDI) within the range 20 ≤ RDI ≤ 50 documented with Level III portable sleep test \*\*\*OR\*\*\*~* Oxygen Desaturation Index (ODI) ≥ 10~Exclusion Criteria:~The patient is excluded if it meets any of the following criteria:~* Extensive periodontal disease;~* Bleeding disorder;~* Bone metabolic disorder~* Immunocompromised~* Diabetes mellitus~* Xerostomia~* Titanium allergy~* Insufficient vertical opening to accommodate treatment with OAm;~* Pregnancy (if a participant becomes pregnant during the trial, the participant will be withdrawn from the study).~* Uncontrolled congestive heart failure (defined as a prior clinical diagnosis, an ejection cut-off of 40% or clinical sign in the opinion of a primary care physician or cardiologist) that makes it unsafe in the opinion of the investigators for the subject to participate in the trial;~* Coronary artery disease unless stable for at least 6 months and considered by the investigators to have a stable disease;~* Any history of angina, myocardial infarction or stroke;~* Any history of major depressive disorder along with current moderate-severe disease;~* Active cancer management (unless in remission for more than 1 year);~* Known renal failure (with need for dialysis)

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Early Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Parapneumonic Effusion and Pleural Empyema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Septated pleural effusion (ultrasonography) in the context of a lower respiratory tract infection~* Frank pleural empyema (pus)~Exclusion Criteria:~* Fibrothorax~* Tuberculous empyema~* Medical thoracoscopy cannot be performed within 24 hours~* Pregnancy~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medical thoracoscopy (Type: EXPERIMENTAL): None
- Simple chest tube drainage (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Isolated orbital fracture, zygomatic fracture, mandibular fracture, or LeFort I/II/III fracture which requires surgical treatment~* Written informed consent obtained~Exclusion Criteria~* Need of intensive care treatment~* Presence of an acute bacterial infection~* Gunshot wounds~* Pathological fracture~* Skull base fracture with rhinoliquorrhea or intracranial emphysema~* History of malignancy or radiation to the head and neck area~* Known hypersensitivity, allergy to penicillin or other beta-lactam antibiotics~* Reduced body weight (\<40kg or BMI\<17), severe renal insufficiency (stage 4 according to the Kidney Disease Outcomes Quality Initiative (KDOQI))~* Insufficient patient compliance

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
- 2 (Type: PLACEBO_COMPARATOR): Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endophthalmitis Cultures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all adult patients age 18 or greater presenting with bacterial endophthalmitis to the Vanderbilt Eye Institute and who grow positive cultures~Exclusion Criteria:~* Patients \< 18 years of age or those patients without positive cultures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Endophthalmitis cultures (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Muscle Atrophy in Patients With Severe Sepsis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
A) Inclusion Criteria~1. Age ≥ 18 years~2. Required mechanical ventilation for at least 24 hours~B) Exclusion Criteria~1. Ventilator liberation anticipated in the next 24 hours~   a. Rationale: short duration of illness anticipated, preventing achievement of primary endpoint~2. Known or suspected acute diagnosis of neuromuscular disease causing diffuse or lower extremity weakness (e.g. CVA, spinal cord injury or lesion, Muscular dystrophy, Myasthenia Gravis, GBS)~   a. Rationale: chronic lower extremity weakness will impact anticipated physical recovery and relevance of atrophy observations~3. Pre-existing lower extremity weakness caused by prior injury, neuromuscular or joint disease~   a. Rationale: Inability to participate in usual care therapy and CPM. Impacts functional recovery~4. Wounds, dressings or injuries of the lower extremities or pelvis that prevent muscle testing or CPM~   a. Rationale: Inability to participate in US, exam or CPM~5. Patient's family, physician, or both not in favor of aggressive treatment of patient that includes life-sustaining treatments or the presence of an advance directive indicating the same a. Rationale: Unlikely to survive to seven day endpoint~6. More than seventy-two hours of continuous mechanical ventilation previously during this hospitalization~   a. Rationale: Atrophy mechanisms already active and may degrade ability to detect early changes.~7. Non-English speaking subject or legally authorized representative~   a. Rationale: This study does not have the funding necessary to translate consents and inability to ensure cooperation with testing.~8. Subject and/or Legally authorized representative unavailable to provide informed consent~9. Subject is a Prisoner~10. Pregnancy (excluded from CPM portion only) a. Rationale: Pregnant patients can develop the supine hypotensive syndrome (where the uterus compromises venous return due to compression of the IVC). This typically occurs only after 20 weeks gestation. To assure safety, any patient who self identifies as pregnant or has a positive urine pregnancy test on admission will not be offered CPM since it requires extended periods in the supine position.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPM device (Type: None): a CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues